The interests of Rafarma in this agreement will be represented by the company RAFA Therapeutics Uzbekistan, the company said.

In accordance with the agreement, BLOCK will undertake the design of the future complex, including a system of clean laboratory rooms with all the necessary equipment within the framework of the project. The centerpiece will be a project for a plant to produce drugs from human blood plasma with a potential processing capacity of more than 1 million liters of plasma per year and an investment volume of more than $50 million dollars. Its launch will allow Uzbekistan to become one of the 10 countries in the world with the largest fractionation plants for the processing of blood components.

“We plan to complete the design work in April 2022 and begin construction of the first phase of the plant in the summer of 2022,” the company said.

This latest development is part of Rafarma Pharmaceuticals’ previous announcement to build a scientific and pharmaceutical complex in the territory of the Tashkent Pharma Park by the end of 2026. At the first stage, it is planned to organize the production of cancer drugs and drugs from human donor blood plasma. At the second stage, a complex will be built for the production of drugs based on antibodies (-MABs) and radiopharmaceuticals used for the diagnosis and treatment of various types of cancer. In addition to modern high-tech production lines, the project provides for the creation of a network of laboratories for the collection of blood plasma, the total investment is $85 million dollars. Experts recognize these construction plans as the largest innovative project of the industrial zone of the Tashkent Pharma Park pharmaceutical cluster.